Ketamine for Neuropathic Pain: Optimal Dosing
Discussed on the PainExam podcast
Claim CME Credit
New York Based Interventional Pain Physician, David Rosenblum MD discusses IV Ketamine for Neuropathic Pain and is offering infusion therapy for chronic pain, depression and other conditions in his Brooklyn and Garden City Pain Management Offices. Patients can make an appointment at www.AABPpain.com or call 718 436 7246 or 516 482 7246

Ketamine was originally synthesized in the 1960s as a safer alternative to phencyclidine, providing dissociative analgesic and amnestic effects. Early evidence of ketamine's effectiveness in treating neuropathic pain came from clinical case reports focusing on nerve injury management in patients with oncologic diseases. Over time, ketamine infusions have been investigated for their potential in treating various conditions such as complex regional pain syndrome (crps), spinal cord injury, phantom limb pain, postherpetic neuralgia, fibromyalgia, and oncologically mediated neuropathic pain. Prospective studies have also suggested potential benefits of ketamine infusion therapy in treating trigeminal neuropathic pain, acute and chronic migraines, and temporomandibular pain. Retrospective studies have contributed valuable data on the clinical use of ketamine infusions.
Ketamine acts as a noncompetitive antagonist of the n-methyl-d-aspartic acid receptor, exerting significant modulatory effects on the transmission of nociceptive signals. However, the relief experienced with ketamine therapy often surpasses the expected duration based on its plasma half-life, suggesting additional mechanisms at play in alleviating neuropathic pain. Ketamine also influences other receptors and ion channels, including -amino-3-hydroxy-5-methyl-4-isoxazole propionate receptors, kainate receptors, -aminobutyric acid receptors, l-type calcium channels, -opioid receptors, and muscarinic and monoaminergic receptors. It may also inhibit inducible nitric oxide synthase, contributing to its analgesic effects. Ketamine has been found effective at subanesthetic doses for managing postoperative pain, reducing opioid requirements, and mitigating nausea and vomiting with minimal side effects. Its pharmacokinetic properties include redistribution half-life, elimination, and rapid blood-brain barrier passage.

Despite ketamine's widespread use, there is currently no consensus on an optimal intravenous (iv) ketamine infusion protocol for treating neuropathic pain. The variety of existing protocols and their associated indications makes it challenging to conduct a meta-analysis. Therefore, the goals of this review are to identify common components of ketamine infusion protocols that lead to prolonged pain relief, minimal side effects, and increased efficacy in treating neuropathic pain. Additionally, the review calls for further clinical studies to establish tailored ketamine infusion protocols for specific neuropathic pain conditions. It is important to note that many studies lack reporting on changes in functional status, which limits their inclusion in the analysis. The aim of this study is not to provide recommendations or assess the strength of existing recommendations regarding the use of ketamine infusions, as the current literature does not support such analysis.